We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03016715
Recruitment Status : Unknown
Verified October 2017 by Premier Specialists, Australia.
Recruitment status was:  Recruiting
First Posted : January 10, 2017
Last Update Posted : October 24, 2017
Information provided by (Responsible Party):
Premier Specialists, Australia

Brief Summary:
: Epidermolysis bullosa (EB) simplex is a rare orphan disease caused by a mutation in DNA leading to abnormal dominant keratins in the skin. Patients with EB simplex develop lifelong painful thick soles on their feet, and current standard of care is supportive. This pilot study will target the dominant mutant keratin proteins in the skin to ameliorate the severity of EB simplex. The purpose is to improve the function of EB simplex feet with an application of topical sirolimus, 2%. The investigators plan on inhibiting the mTOR pathway to down regulate the translation of defective keratin proteins and work through anti proliferative pathways.

Condition or disease Intervention/treatment Phase
Epidermolysis Bullosa Simplex Epidermolysis Bullosa Simplex Kobner Weber-Cockayne Syndrome Drug: Sirolimus 2% Drug: Vehicle Phase 2

Detailed Description:

The proposed 40 week pilot study being conducted is a prospective, double-blind, randomized, placebo-controlled crossover study. Participants will be assigned to treat both feet with either topical sirolimus, 2% cream daily or placebo (vehicle-control) for 12 weeks, followed by a 4 week washout period, then re-treatment to both feet will occur by the cross-over intervention.

These studies will exploit the naturally occurring transcriptional regulation of keratin sequences, the known gene aberration causing EB simplex, and assess the potential for mTOR pathway inhibition in treatment of the patient's plantar lesions. The objective of this study is to assess (1) the safety of topical rapamycin for plantar lesions for the treatment of EB simplex, and 2) test if topical rapamycin to improves the clinical severity of lesional skin, including pain and itch, in subjects with EB simplex at the end of treatment versus baseline and compared to an intrasubject placebo treated control. Wound size measurement, quality of life evaluation will be assessed using epidermolysis bullosa (QOLEB), and EB disease activity and Scarring Index (EBDASI). With the results of this pilot study, physicians would be able to transition from supportive care (the current state of the art for EB simplex) to targeted molecular therapeutics, leading to improved mobility and quality of life for patients with EB simplex.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)
Study Start Date : May 2016
Estimated Primary Completion Date : June 2019

Arm Intervention/treatment
Experimental: Treatment
Sirolimus, 2% topical ointment will be used during randomization
Drug: Sirolimus 2%
Placebo Comparator: Vehicle
A placebo topical ointment will be used during randomization.
Drug: Vehicle
Other Name: Placebo

Primary Outcome Measures :
  1. Foot Health Status Questionnaire [ Time Frame: Change from Baseline to End of Treatment completion at 32 Week ]
    Foot function utilizing the validated Foot Health Status Questionnaire (FHSQ) as a change from baseline to the end of each treatment.

Secondary Outcome Measures :
  1. FitBit® / pedometer [ Time Frame: Baseline and through study treatment completion at 32-weeks] ]
  2. Plantar defect size using 3D Photography [ Time Frame: Change in total defect area from Baseline, clinical visits at Week 4, Week 12, Week 16, Week 28, through study treatment completion at 32-weeks ]
    Plantar defect size measurements using 3D photography (% change in total defect area) from baseline to the end of each treatment.

  3. Child Dermatological Quality of Life Questionnaire [ Time Frame: Baseline through study treatment completion at 32 weeks ]
  4. The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) Disease Severity Scale [ Time Frame: Baseline and through study treatment completion at 32-weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects must:

  • Be capable of understanding the purpose and risks of the study and sign a written Informed Consent Form (ICF); Legally authorized representative of subjects willing and able to give consent for children 5-18 yo
  • Be male or female with a diagnosis of EBS
  • Minimum EBDASI feet activity score of 2/10
  • Age - 5 years or older
  • Ability to complete 12 study visits within a 40-week period, each for approximately 30-60 minutes.

Anticipated life expectancy ≥52 weeks

  • Males and females of childbearing potential should be using an effective means of contraception.
  • Laboratory values within the range of normal for the participating institution unless the PI feels they are not clinically relevant
  • Be able to comply with all study requirements

Exclusion Criteria:

  • Allergy to sirolimus or components of the vehicle ointment
  • Pregnancy, breast feeding
  • Prior history of liver disease
  • Serious known concurrent medical illness or infection, which could potentially present a safety risk and/or prevent compliance with the requirements of the treatment program.
  • Known immunodeficiency virus or syndrome including those with:
  • Acquired Immunodeficiency Syndrome (AIDS)
  • Human Immunodeficiency Virus (HIV)
  • Hepatitis B
  • Prior history of grafting surgeries or other surgeries in the dermatologic treatment area
  • History of significant condition in the dermatologic treatment area such as trauma, which could impair evaluation for the treatment of EBS or non-healing chronic wound.
  • Use of other investigational drugs within 30 days of the screening visit and/or has not recovered from any side effects of prior investigational drugs or procedure in the affected area (e.g., a biopsy).
  • Use of acitretin within the last 1 month
  • Use of Roaccutane within last 3 months
  • Botox injections to the feet within the last 6 months.
  • Participant is planning extra physical activities within the next 3 months.
  • Amputated foot

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03016715

Layout table for location contacts
Contact: Dedee F Murrell, MD d.murrell@unsw.edu.au
Contact: Charmaine Peras premierspecnurse@gmail.com

Layout table for location information
Australia, New South Wales
Premier Specialists Recruiting
Sydney, New South Wales, Australia, 2217
Contact: Charmaine Peras    61 02 9598 5800    premierspecnurse@gmail.com   
Principal Investigator: Dedee F Murrell, MD         
Sub-Investigator: Charlotte E Gollins, MBChB         
Sub-Investigator: Anes Yang         
Sub-Investigator: Melissa Radjenovic         
Sponsors and Collaborators
Premier Specialists, Australia
Layout table for investigator information
Study Chair: Dedee F Murrell, MD University of New South Wales

Layout table for additonal information
Responsible Party: Premier Specialists, Australia
ClinicalTrials.gov Identifier: NCT03016715    
Other Study ID Numbers: 2016-05-413
First Posted: January 10, 2017    Key Record Dates
Last Update Posted: October 24, 2017
Last Verified: October 2017
Keywords provided by Premier Specialists, Australia:
Epidermolysis bullosa simplex
Additional relevant MeSH terms:
Layout table for MeSH terms
Cockayne Syndrome
Epidermolysis Bullosa
Epidermolysis Bullosa Simplex
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Nervous System Diseases
Abnormalities, Multiple
DNA Repair-Deficiency Disorders
Metabolic Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antineoplastic Agents
Antifungal Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs